About the Company
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BPMC News
Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares
On the day of the sale, shares of Blueprint Medicines Corp were trading at $90.4, giving the company a market capitalization ...
Blueprint Medicines files patent for treatment for diseases related to mutant kit and PDGFRA
Discover how Blueprint Medicines Corp. is revolutionizing treatment for mutant KIT and PDGFRa-related diseases with their patented compounds. Learn more about their non-brain penetrant profile and ...
Blueprint Medicines Corporation: Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of Blueprint Medicines' Board ...
Chutes & Ladders—Voyager plucks another Biogen exec for top post
Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research ...
Incyte’s Hold Rating: Balancing Clinical Promise Against Financial and Market Position
JMP Securities analyst Reni Benjamin has reiterated their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has ...
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
For those with $1,000 to spare, let's consider two healthcare stocks worth investing in and holding onto for a long time: ...
Tallahassee couple behind city's first 3D-printed house makes $315K pitch to Blueprint
Kyndra Light, CEO of Gulf Coast Additive Manufacturing & Design, made a first pitch at the Feb. 29 Blueprint meeting for $315 ...
Out of the lab and into the factory
Biotech companies are now betting on the Seattle area, where "in terms of where biomanufacturing is ... is probably at its ...
2 Top Dividend Stocks to Buy Hand Over Fist
Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase ...
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
Madrigal Pharmaceuticals (MDGL) stock surges as Wall Street welcomes the company's new NASH medication, Rezdiffra. Read more ...
Madrigal granted FDA approval for NASH therapy
The U.S. FDA approves Madrigal Pharmaceuticals' (MDGL) resmetirom as the first therapy for NASH, a liver condition with no approved treatments. Read more here.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, ...
Loading the latest forecasts...